# Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Older Patients With Type2 Diabetes Insufficiently Controlled on Their Current Antidiabetic Medications

Study · id `cardio:ct-nct02320721` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02320721](<https://clinicaltrials.gov/study/NCT02320721>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02320721

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1014 participants.

## Technical summary

Registry record NCT02320721. Randomized; no masking; primary purpose treatment. Start 2015-01 (registry gives no type); primary completion 2016-05 (actual). Results posted on 2017-07-11.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 1014 participants (enrolled count; ClinicalTrials.gov record NCT02320721, source copy `cardio:ctgov-nct02320721-2020-04-21`, retrieved 2026-10-26)
- Start date: 2015-01 (registry gives no type) (ClinicalTrials.gov record NCT02320721, source copy `cardio:ctgov-nct02320721-2020-04-21`, retrieved 2026-10-26)
- Primary completion: 2016-05 (actual) (ClinicalTrials.gov record NCT02320721, source copy `cardio:ctgov-nct02320721-2020-04-21`, retrieved 2026-10-26)
- Completion: 2016-05 (actual) (ClinicalTrials.gov record NCT02320721, source copy `cardio:ctgov-nct02320721-2020-04-21`, retrieved 2026-10-26)
- Results first posted: 2017-07-11 (ClinicalTrials.gov record NCT02320721, source copy `cardio:ctgov-nct02320721-2020-04-21`, retrieved 2026-10-26)
- Countries: United States; Argentina; Australia; Canada; Colombia; France; Germany; Hungary; Italy; Japan; Mexico; Peru; Poland; Romania; South Korea; Spain; Sweden; United Kingdom (ClinicalTrials.gov record NCT02320721, source copy `cardio:ctgov-nct02320721-2020-04-21`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02320721-2020-04-21`, retrieved 2026-10-26)

## The registry's words

- Brief title: Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Older Patients With Type2 Diabetes Insufficiently Controlled on Their Current Antidiabetic Medications
- Acronym: SENIOR
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Insulin Glargine (HOE901 - U300)
- Intervention (Drug): Insulin Glargine (HOE901 - U100)
- Intervention (Drug): Background therapy
- Lead sponsor: Sanofi
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Sanofi (`cardio:org-sanofi`)

## Provenance

Content hash: 87539cd63bd872c9c199d1d5c3dd8ab6724f79ba30e6139ddce67ceb703cacbe
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
